Study on Using KIR-Favorable Donors for Transplants in Children with Certain Blood Cancers

Program Overview

This study is testing a new method of bone marrow transplantation for children with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS). The focus is on using donors with specific genetic markers, known as KIR-favorable donors, to see if this can improve survival rates. The study will also look at how different genetic variations in these markers affect the success of the transplant.

Description

Bone marrow transplants are a common treatment for children with high-risk blood cancers like ALL and AML. However, not all children have a perfectly matched donor available. This study is looking at using partially matched family donors with specific genetic markers, called KIR-favorable donors, to see if this can lead to better outcomes.

The study will compare this approach to other methods, such as using umbilical cord blood, which is another option when a fully matched donor isn't available. Researchers will also examine how different genetic variations in these markers affect the success of the transplant.

Previous research has shown promising results using this method, with high survival rates in children who received transplants from KIR-favorable donors. This study aims to confirm these findings in a larger group of patients across multiple centers.

The study will also explore the cost-effectiveness of this approach and how it compares to other transplant methods. By understanding the role of these genetic markers, researchers hope to improve the success rates of bone marrow transplants for children with these serious conditions.

Eligibility Criteria

Locations